Display options
Cite
Wang X, Cui DN, Dai XM, et al. HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis. Front Pharmacol. 2017;8:156doi: 10.3389/fphar.2017.00156.
Wang, X., Cui, D. N., Dai, X. M., Wang, J., Zhang, W., Zhang, Z. J., & Xu, F. G. (2017). HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis. Frontiers in pharmacology, 8156. https://doi.org/10.3389/fphar.2017.00156
Wang, Xu, et al. "HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis." Frontiers in pharmacology vol. 8 (2017): 156. doi: https://doi.org/10.3389/fphar.2017.00156
Wang X, Cui DN, Dai XM, Wang J, Zhang W, Zhang ZJ, Xu FG. HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis. Front Pharmacol. 2017 Mar 30;8:156. doi: 10.3389/fphar.2017.00156. eCollection 2017. PMID: 28424615; PMCID: PMC5371663.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2017 Mar 30;8:156. doi: 10.3389/fphar.2017.00156. eCollection 2017.

HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis.

Frontiers in pharmacology

Xu Wang, Dong-Ni Cui, Xiao-Min Dai, Jing Wang, Wei Zhang, Zun-Jian Zhang, Feng-Guo Xu

Affiliations

  1. Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education (MOE), China Pharmaceutical UniversityNanjing, China.
  2. State Key Laboratory of Natural Medicine, China Pharmaceutical UniversityNanjing, China.
  3. State Key Laboratory for Quality Research in Chinese Medicines, Macau University of Science and TechnologyMacau, China.

PMID: 28424615 PMCID: PMC5371663 DOI: 10.3389/fphar.2017.00156

Abstract

Irinotecan (CPT-11) is a potent chemotherapeutic agent, however, its clinical usage is often limited by the induction of severe gastrointestinal (GI) toxicity, especially late-onset diarrhea. HuangQin Decoction (HQD), commonly used for the treatment of GI ailments, has been proved could significantly ameliorate the intestinal toxicity of CPT-11. To reveal the mechanisms of CPT-11-induced toxicity and the modulation effects of HQD, a previous untargeted metabolomics study was performed and the results indicated that HQD may protect the GI tract by altering the metabolism of bile acids (BAs). Nevertheless, the untargeted assays are often less sensitive and/or efficient. In order to further confirm our previous findings, here in this paper, serum and tissues metabolic profiles of 17 BAs were analyzed using liquid chromatography-tandem mass spectrometry based targeted metabolomics. The results indicated that serum and tissues levels of most BAs were significantly decreased after CPT-11 administration, except some hydrophobic BAs. Co-treatment with HQD could markedly attenuate CPT-11-induced GI toxicity and reverse the alterations of hydrophobic BAs. Despite the fact that the BAs pool size remained unchanged, the balance of BAs had shifted leading to decreased toxicity after HQD treatment. The present study demonstrated for the first time that the precise interaction between HQD, CPT-11-induced intestinal toxicity and BAs' homeostasis.

Keywords: HuangQin Decoction; LC-MS/MS; bile acids; irinotecan (CPT-11); metabolomics

References

  1. Cell Metab. 2013 May 7;17(5):657-69 - PubMed
  2. Oncol Rep. 2015 May;33(5):2151-60 - PubMed
  3. J Pharmacol Exp Ther. 2013 Jun;345(3):473-82 - PubMed
  4. Lancet Oncol. 2005 Feb;6(2):93-102 - PubMed
  5. World J Gastroenterol. 2009 Jul 7;15(25):3134-41 - PubMed
  6. Cell Death Differ. 1999 Sep;6(9):842-54 - PubMed
  7. Biochim Biophys Acta. 2005 Jun 15;1735(1):59-67 - PubMed
  8. Biochem J. 2001 Jun 1;356(Pt 2):481-6 - PubMed
  9. Int J Mol Sci. 2012 Nov 09;13(11):14634-47 - PubMed
  10. Sci Rep. 2015 Mar 30;5:9384 - PubMed
  11. Infect Immun. 2014 Sep;82(9):3531-41 - PubMed
  12. Anticancer Res. 2009 Oct;29(10):4083-92 - PubMed
  13. Support Care Cancer. 2001 Jun;9(4):258-60 - PubMed
  14. Gastroenterology. 2013 Jan;144(1):145-54 - PubMed
  15. Cancer Chemother Pharmacol. 2014 Feb;73(2):373-80 - PubMed
  16. Cell Metab. 2013 Feb 5;17 (2):225-35 - PubMed
  17. Biochemistry. 2013 Oct 22;52(42):7461-9 - PubMed
  18. Breast Cancer. 2015 Jul;22(4):335-42 - PubMed
  19. J Clin Oncol. 2004 Jul 15;22(14):2918-26 - PubMed
  20. Pharmacol Rev. 2014 Oct;66(4):948-83 - PubMed
  21. Cell Signal. 2008 Dec;20(12):2180-97 - PubMed
  22. Ann Oncol. 2008 Aug;19(8):1417-22 - PubMed
  23. Nature. 2012 Jul 5;487(7405):104-8 - PubMed
  24. Cancer Chemother Pharmacol. 2000;46(3):211-20 - PubMed
  25. Invest New Drugs. 2001;19(4):341-3 - PubMed
  26. Ann Oncol. 2003 Mar;14 (3):388-94 - PubMed
  27. Oncol Rep. 2009 Sep;22(3):621-9 - PubMed
  28. Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G372-81 - PubMed
  29. J Lab Clin Med. 1979 Nov;94(5):661-74 - PubMed
  30. Cancer Biol Ther. 2008 Dec;7(12 ):1919-25 - PubMed
  31. Br J Cancer. 1999 Oct;81(3):440-8 - PubMed
  32. Gut. 2011 Apr;60(4):432-3 - PubMed
  33. J Biol Chem. 2000 Jul 21;275(29):21805-8 - PubMed
  34. Phytomedicine. 2010 Mar;17(3-4):161-9 - PubMed
  35. Toxicol Appl Pharmacol. 2016 Jan 15;291:21-7 - PubMed
  36. Nat Commun. 2014 Sep 03;5:4573 - PubMed
  37. Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G1000-8 - PubMed
  38. Cancer Chemother Pharmacol. 2016 Apr;77(4):713-22 - PubMed
  39. PLoS One. 2012;7(7):e36075 - PubMed
  40. Dig Dis Sci. 1980 Jun;25(6):433-8 - PubMed
  41. J Pharmacol Exp Ther. 2006 Oct;319(1):82-104 - PubMed
  42. Front Nutr. 2016 Oct 10;3:46 - PubMed
  43. Biochim Biophys Acta. 2001 Feb 16;1525(1-2):125-9 - PubMed
  44. Biochim Biophys Acta. 2015 Jan;1851(1):19-29 - PubMed
  45. Am J Chin Med. 2015;43(1):1-23 - PubMed
  46. Int J Colorectal Dis. 2004 Nov;19(6):609-10 - PubMed
  47. Am J Physiol. 1980 Apr;238(4):G321-5 - PubMed
  48. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4523-30 - PubMed
  49. Front Biosci (Landmark Ed). 2009 Jan 01;14:4719-45 - PubMed
  50. J Nutr. 2004 Feb;134(2):483-6 - PubMed
  51. Oncology. 2001;60(3):207-13 - PubMed
  52. Cancer Res. 2002 Oct 15;62(20):5778-84 - PubMed
  53. Clin Colorectal Cancer. 2011 Jun;10 (2):85-96 - PubMed
  54. Sci Transl Med. 2010 Aug 18;2(45):45ra59 - PubMed
  55. J Gastroenterol. 2015 Jul;50(7):707-19 - PubMed
  56. J Pharmacol Exp Ther. 2000 Oct;295(1):233-8 - PubMed

Publication Types